Veru Inc. (NASDAQ: VERU) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens. The company posted a narrower loss for Q2 as the substantial growth in prescription sales of FC2 drove the top-line higher.
On Tuesday, Veru received FDA permission to initiate a phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. Veru has initiated the study and expects the first patient to be dosed within 2 weeks.
The company believes that VERU-111, a microtubule depolymerization agent that has broad antiviral activity, could be effective against the SARS CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to cause infection.
Past Performance
Most Popular
Earnings Preview: Accenture (ACN) likely had a strong start to fiscal 2025
For Accenture plc. (NYSE: ACN), 2024 was a fruitful year marked by positive financial performance. The professional service firm effectively navigated a challenging market environment leveraging its agile business model
Signet Jewelers (SIG): Fashion remains a strong point for the jewelery retailer
Shares of Signet Jewelers Limited (NYSE: SIG) were down over 3% on Tuesday. The stock has dropped 12% over the past three months. The company faced challenges in the third
Pfizer (PFE) reaffirms FY24 forecast; provides FY25 guidance
Pharmaceutical company Pfizer Inc. (NYSE: PFE) Tuesday reaffirmed its financial outlook for fiscal 2024 and provided guidance for fiscal 2025. The company said it achieved the goal of $4 bln
